JP2006505627A - 新規エフェクター接合体、それらの生成方法及びそれらの医薬使用 - Google Patents
新規エフェクター接合体、それらの生成方法及びそれらの医薬使用 Download PDFInfo
- Publication number
- JP2006505627A JP2006505627A JP2005506073A JP2005506073A JP2006505627A JP 2006505627 A JP2006505627 A JP 2006505627A JP 2005506073 A JP2005506073 A JP 2005506073A JP 2005506073 A JP2005506073 A JP 2005506073A JP 2006505627 A JP2006505627 A JP 2006505627A
- Authority
- JP
- Japan
- Prior art keywords
- dione
- dihydroxy
- tetramethyl
- methyl
- dioxa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(*)C(CC(*)C(*)(*)ONNC(C)(*)C(*)(C(*)(*)C(C1(C)*)=N)OC)**CC1OI Chemical compound CC(*)C(CC(*)C(*)(*)ONNC(C)(*)C(*)(C(*)(*)C(C1(C)*)=N)OC)**CC1OI 0.000 description 6
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10234975A DE10234975A1 (de) | 2002-07-31 | 2002-07-31 | Neue Effektor-Konjugate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
DE10305098A DE10305098A1 (de) | 2003-02-07 | 2003-02-07 | Neue Effektor-Konjugate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
US45167303P | 2003-03-05 | 2003-03-05 | |
PCT/EP2003/008483 WO2004012735A2 (fr) | 2002-07-31 | 2003-07-31 | Nouveaux conjugues d'effecteurs, procedes permettant de les produire et utilisation pharmaceutique de ceux-ci |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2006505627A true JP2006505627A (ja) | 2006-02-16 |
Family
ID=31498923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005506073A Pending JP2006505627A (ja) | 2002-07-31 | 2003-07-31 | 新規エフェクター接合体、それらの生成方法及びそれらの医薬使用 |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1524979A2 (fr) |
JP (1) | JP2006505627A (fr) |
KR (1) | KR20050026033A (fr) |
AU (1) | AU2003253365A1 (fr) |
BR (1) | BR0313043A (fr) |
CA (1) | CA2492437A1 (fr) |
CO (1) | CO5700741A2 (fr) |
EC (1) | ECSP055626A (fr) |
HR (1) | HRP20050186A2 (fr) |
IL (1) | IL166039A0 (fr) |
IS (1) | IS7708A (fr) |
MX (1) | MXPA05001282A (fr) |
NO (1) | NO20051038L (fr) |
NZ (1) | NZ537870A (fr) |
PL (1) | PL374528A1 (fr) |
WO (1) | WO2004012735A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006511469A (ja) * | 2002-09-13 | 2006-04-06 | ノバルティス アクチエンゲゼルシャフト | エポチロン誘導体の新規製造方法、新規エポチロン誘導体ならびに当該製造方法のための中間体およびそれらの製造方法 |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1161430A2 (fr) * | 1999-02-11 | 2001-12-12 | Schering Aktiengesellschaft | Derives d'epothilone, leur procede de production et leur utilisation pharmaceutique |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
CN1759115A (zh) | 2002-08-23 | 2006-04-12 | 索隆-基特林癌症研究协会 | 埃坡霉素(epothilone),合成埃坡霉素的中间体,其类似物及其用途 |
DE10256982A1 (de) | 2002-12-05 | 2004-06-24 | Schering Ag | Neue Effektor-Konjugate, Verfahren zu Ihrer Herstellung und Ihre Pharmazeutische Verwendung |
JP2006510626A (ja) * | 2002-12-05 | 2006-03-30 | シエーリング アクチエンゲゼルシャフト | 増殖疾患の処理における部位特異的供給のためのエポチロン類似体 |
DE602005003453T2 (de) * | 2004-01-30 | 2008-09-25 | Bayer Schering Pharma Aktiengesellschaft | Neue effektor-konjugate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung |
US7541330B2 (en) | 2004-06-15 | 2009-06-02 | Kosan Biosciences Incorporated | Conjugates with reduced adverse systemic effects |
WO2006012527A1 (fr) | 2004-07-23 | 2006-02-02 | Endocyte, Inc. | Groupes de liaison bivalents et conjugués de ceux-ci |
AR061181A1 (es) | 2006-05-25 | 2008-08-13 | Bristol Myers Squibb Co | Compuestos de aziridinil-epotilona |
PE20080102A1 (es) * | 2006-05-25 | 2008-02-11 | Bristol Myers Squibb Co | Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos |
CN101678124A (zh) | 2007-03-14 | 2010-03-24 | 恩多塞特公司 | 结合配体连接的微管溶素递药缀合物 |
EP2152717A1 (fr) | 2007-05-25 | 2010-02-17 | Bristol-Myers Squibb Company | Procedes de fabrication de composes et d'analogues d'epothilone |
EP3569251A1 (fr) | 2007-06-25 | 2019-11-20 | Endocyte, Inc. | Conjugués contenant des lieurs espaceurs hydrophiles |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
CA2703491C (fr) | 2007-10-25 | 2017-06-13 | Endocyte, Inc. | Tubulysines et leurs procedes de preparation |
IT1401451B1 (it) * | 2010-06-10 | 2013-07-26 | Chemi Spa | Nuovo processo di preparazione di 2-idrossi-4-fenil-3,4-diidro-2h-cromen-6-il-metanolo e (r)-2-[3-(diisopropilammino)-1-fenilpropil]-4-(idrossimetil)fenolo. |
US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
AU2013331440A1 (en) | 2012-10-16 | 2015-04-30 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
MX2019004434A (es) * | 2016-10-17 | 2019-09-26 | Pfizer | Anticuerpos anti-edb y conjugados anticuerpo-fármaco. |
KR102377416B1 (ko) * | 2017-06-30 | 2022-03-21 | 엘지디스플레이 주식회사 | 표시장치 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK130984A (da) * | 1983-03-07 | 1984-09-08 | Smithkline Beckman Corp | Leukotrien-antagonister |
IL107400A0 (en) * | 1992-11-10 | 1994-01-25 | Cortech Inc | Bradykinin antagonists |
US5942555A (en) * | 1996-03-21 | 1999-08-24 | Surmodics, Inc. | Photoactivatable chain transfer agents and semi-telechelic photoactivatable polymers prepared therefrom |
US20020058286A1 (en) * | 1999-02-24 | 2002-05-16 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
AU2001243372A1 (en) * | 2000-03-01 | 2001-09-12 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
NZ546497A (en) * | 2000-04-28 | 2008-04-30 | Kosan Biosciences Inc | Production of polyketides |
US6441213B1 (en) * | 2000-05-18 | 2002-08-27 | National Starch And Chemical Investment Holding Corporation | Adhesion promoters containing silane, carbamate or urea, and donor or acceptor functionality |
AU2001266583A1 (en) * | 2000-05-26 | 2001-12-11 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
DE10041221A1 (de) * | 2000-08-22 | 2002-03-14 | Deutsches Krebsforsch | Verfahren zur Herstellung von wasserlöslichen Saccharidkonjugaten und Saccharidmimetika durch Diels-Alder-Reaktion und ihre Verwendung als Therapeutika oder Diagnostika |
GB0116143D0 (en) * | 2001-07-02 | 2001-08-22 | Amersham Pharm Biotech Uk Ltd | Chemical capture reagent |
-
2003
- 2003-07-31 PL PL03374528A patent/PL374528A1/xx not_active Application Discontinuation
- 2003-07-31 IL IL16603903A patent/IL166039A0/xx unknown
- 2003-07-31 WO PCT/EP2003/008483 patent/WO2004012735A2/fr active Application Filing
- 2003-07-31 EP EP03743752A patent/EP1524979A2/fr not_active Withdrawn
- 2003-07-31 AU AU2003253365A patent/AU2003253365A1/en not_active Abandoned
- 2003-07-31 CA CA002492437A patent/CA2492437A1/fr not_active Abandoned
- 2003-07-31 KR KR1020057001569A patent/KR20050026033A/ko not_active Application Discontinuation
- 2003-07-31 JP JP2005506073A patent/JP2006505627A/ja active Pending
- 2003-07-31 MX MXPA05001282A patent/MXPA05001282A/es not_active Application Discontinuation
- 2003-07-31 NZ NZ537870A patent/NZ537870A/en unknown
- 2003-07-31 BR BR0313043-6A patent/BR0313043A/pt not_active IP Right Cessation
-
2005
- 2005-02-23 IS IS7708A patent/IS7708A/is unknown
- 2005-02-24 EC EC2005005626A patent/ECSP055626A/es unknown
- 2005-02-24 CO CO05017568A patent/CO5700741A2/es not_active Application Discontinuation
- 2005-02-25 HR HR20050186A patent/HRP20050186A2/hr not_active Application Discontinuation
- 2005-02-25 NO NO20051038A patent/NO20051038L/no not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006511469A (ja) * | 2002-09-13 | 2006-04-06 | ノバルティス アクチエンゲゼルシャフト | エポチロン誘導体の新規製造方法、新規エポチロン誘導体ならびに当該製造方法のための中間体およびそれらの製造方法 |
Also Published As
Publication number | Publication date |
---|---|
MXPA05001282A (es) | 2005-04-28 |
BR0313043A (pt) | 2005-06-14 |
ECSP055626A (es) | 2005-04-18 |
WO2004012735A3 (fr) | 2004-05-27 |
EP1524979A2 (fr) | 2005-04-27 |
NZ537870A (en) | 2007-03-30 |
IS7708A (is) | 2005-02-23 |
KR20050026033A (ko) | 2005-03-14 |
CO5700741A2 (es) | 2006-11-30 |
PL374528A1 (en) | 2005-10-31 |
NO20051038L (no) | 2005-04-06 |
IL166039A0 (en) | 2006-01-15 |
HRP20050186A2 (en) | 2005-10-31 |
WO2004012735A2 (fr) | 2004-02-12 |
CA2492437A1 (fr) | 2004-02-12 |
AU2003253365A1 (en) | 2004-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006505627A (ja) | 新規エフェクター接合体、それらの生成方法及びそれらの医薬使用 | |
US7335775B2 (en) | Effector conjugates, process for their production and their pharmaceutical use | |
EP1718340B1 (fr) | Nouveaux conjugues d'effecteurs, leurs procedes de production et leur utilisation pharmaceutique | |
JP4024003B2 (ja) | 6−アルケニル−,6−アルキニル−及び6−エポキシ−エポチロン誘導体類、それらの生成方法、及び医薬製剤へのそれらの使用 | |
US6930102B2 (en) | 16-halogen-epothilone derivatives, process for their production, and their pharmaceutical use | |
AU648313B2 (en) | Novel CC-1065 analogs | |
JP2017531027A (ja) | リンカー及びadcへのその応用 | |
US20100168179A1 (en) | 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations | |
JP2020534300A (ja) | タイランスタチン類似体 | |
US20050234247A1 (en) | New effector conjugates, process for their production and their pharmaceutical use | |
US6906188B2 (en) | Method for synthesizing epothilones and epothilone analogs | |
JP2003531206A (ja) | 9−オキサ−エポシロン−誘導体の製造方法及び医薬的調製におけるこれらの使用 | |
DE10305098A1 (de) | Neue Effektor-Konjugate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung | |
DE10234975A1 (de) | Neue Effektor-Konjugate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060703 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100309 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100803 |